A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

Inclusion Criteria:

- adult patients 18-80 years of age with active RA;

- patients who participated in MabThera study WA17042, and completed to at least the
Week 24 visit;

- eligible for re-treatment, based on clinical symptoms;

- patients of reproductive potential must be using reliable contraceptive methods.

Exclusion Criteria:

- patients who participated in MabThera study WA17042 but withdrew into the safety
follow-up;

- current treatment with any other disease-modifying antirheumatic drug (apart from
methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;

- development of any new contraindications to receiving MabThera;

- women who are pregnant or breast-feeding.